Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18

BACKGROUND: Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Doxil on surviving tumor cell immunophenotype were investigated. METHODS: Using ID...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Alagkiozidis, Ioannis, Facciabene, Andrea, Carpenito, Carmine, Benencia, Fabian, Jonak, Zdenka, Adams, Sarah, Carroll, Richard G, Gimotty, Phyllis A, Hammond, Rachel, Danet-Desnoyers, Gwen-äel, June, Carl H, Powell, Daniel J, Coukos, George
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2009
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2797002/
https://ncbi.nlm.nih.gov/pubmed/20003308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-104
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge